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Introduction
1,2,5,6,9,10-hexabromocyclododecane 
(HBCD) is a brominated flame retardant (BFR) 
produced globally as a commercial-mixture 
(CM-HBCD). CM-HBCD, which is added 
to consumer products, enters the environment 
during production and leaches from goods 
in use or disposal (EC 2008). Food and dust 
ingestion and inhalation are considered relevant 
human exposure routes in the United States, 
Canada, European Union (EU), China, New 
Zealand, and Africa (Ali et al. 2012; Kalachova 
et al. 2012; Shoeib et al. 2012; Asante et al. 
2013; Ni and Zeng 2013; Eljarrat et al. 2014; 
Fromme et al. 2014). CM-HBCD is lipophilic 
(log Kow 5.6), resistant to environmental degra-
dation, has half-lives of 51, 1,440, and 5,760 hr 
in air, water, and sediment, respectively, trans-
ports over long distances, and bioaccumulates in 
human and animal tissue (EC 2008).
CM-HBCD was added to the 2013 
Stockholm Convention list for global 
elimination following PBT (persistence, 
 bioaccumulation, and toxicity) evaluation 
with a 5-year exemption for building insula-
tion (see http://chm.pops.int/default.aspx). 
In 2014, the U.S. Environmental Protection 
Agency (EPA) nominated CM-HBCD to be 
added to the Toxic Release Inventory (U.S. 
EPA 2014b), and to the U.S. EPA’s Design 
for the Environment Alternatives Assessments 
(U.S. EPA 2014a). In the EU, CM-HBCD 
is listed as a substance of very high concern 
under Annex XIV of REACH (Regulation 
for Registration, Evaluation, Authorisation 
and Restriction of Chemicals); after 21 August 
2015, only approved applications may use 
the chemical (ECHA 2009). Currently, 
under the Commission for Environmental 
Cooperation (CEC), Canada, Mexico, and 
the United States are evaluating the presence 
and  migration of CM-HBCD from consumer 
products (CEC 2015). CM-HBCD is 
currently on the U.S. EPA Integrated Risk 
Information System (IRIS) program agenda, 
but an anticipated date for completion has not 
yet been  determined (U.S. EPA 2015).
CM-HBCD public health concerns 
focus on adverse effects to infants and 
young children, as it has been detected in 
human fetal livers (Rawn et al. 2014), and 
experimental evidence suggests that it can 
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Background: Hexabromocyclododecane (HBCD) is a high production volume brominated flame 
retardant added to building insulation foams, electronics, and textiles. HBCD is a commercial 
mixture (CM-HBCD) composed of three main stereoisomers: α-HBCD (10%), β-HBCD (10%), 
and γ-HBCD (80%). A shift from the dominant stereoisomer γ-HBCD to α-HBCD is detected in 
humans and wildlife.
oBjectives: Considering CM-HBCD has been implicated in neurodevelopment and endocrine 
disruption, with expected metabolism perturbations, we performed metabolomics on mice serum 
obtained during a window-of-developmental neurotoxicity to draw correlations between early-life 
exposures and developmental outcomes and to predict health risks.
Methods: Six female C57BL/6 mice at postnatal day (PND) 10 were administered a single gavage 
dose of α-, γ-, or CM-HBCD at 3, 10, and 30 mg/kg. Nuclear magnetic resonance metabolomics 
was used to analyze 60 μL serum aliquots of blood collected 4 days post-oral exposure.
results: Infantile mice exposed to α-, γ-, or CM-HBCD demonstrated differences in endogenous 
metabolites by treatment and dose groups, including metabolites involved in glycolysis, gluco-
neogenesis, lipid metabolism, citric acid cycle, and neurodevelopment. Ketone bodies, 3-hydroxy-
butyrate, and acetoacetate, were nonstatistically elevated, when compared with mean control 
levels, in all treatment and dose groups, while glucose, pyruvate, and alanine varied. Acetoacetate 
was significantly increased in the 10 mg/kg α-HBCD and was nonsignificantly decreased with 
CM-HBCD. A third ketone body, acetone, was significantly lower in the 30 mg/kg α-HBCD 
group with significant increases in pyruvate at the same treatment and dose group. Metabolites 
significant in differentiating treatment and dose groups were also identified, including decreases in 
amino acids glutamate (excitatory neurotransmitter in learning and memory) and phenylalanine 
(neurotransmitter precursor) after α-HBCD and γ-HBCD exposure, respectively.
conclusions: We demonstrated that 4 days following a single neonatal oral exposure to α-, γ-, 
and CM-HBCD resulted in different serum metabolomic profiles, indicating stereoisomer- and 
mixture-specific effects and possible mechanisms of action.
citation: Szabo DT, Pathmasiri W, Sumner S, Birnbaum LS. 2017. Serum metabolomic 
profiles in neonatal mice following oral brominated flame retardant exposures to hexabromocyclo-
dodecane (HBCD) alpha, gamma, and commercial mixture. Environ Health Perspect 125:651–659; 
http://dx.doi.org/10.1289/EHP242
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impact thyroid hormone (TH), energy and 
lipid metabolism, and neurodevelopment. 
Young mice (6–20 weeks) that were exposed 
weekly to 700 μg/kg or 35 μg/kg CM-HBCD 
in a high-fat diet experience weight gain 
and metabolic dysfunction (disrupting lipid 
and glucose homeostasis), possibly acceler-
ating obesity progression (Yanagisawa et al. 
2014). A two-generation Crl:CD(SD) rat 
(Ema et al. 2008) and pregnant Sprague-
Dawley rat study (Saegusa et al. 2009) found 
no observed adverse effect level (NOAEL)
at 150 ppm and 100 ppm CM-HBCD 
doses, respectively, while higher levels of 
CM-HBCD led to disruption of TH levels. 
Learning and memory and other develop-
mental neurotoxicity (DNT) end points were 
observed in 3-month-old mice after a single 
oral exposure of either 0.9 mg HBCD/kg or 
13.5 mg HBCD/kg to neonatal NMRI mice 
(Eriksson et al. 2006). Pregnant Long-Evans 
rats, gavaged gestation day 1 to parturition 
with 3, 10, or 30 mg/kg HBCD, produced 
offspring with long-term behavioral impair-
ments (Miller-Rhodes et al. 2014). PND22 
Balb/c mice exposed 28 days to fish-based 
diets spiked with CM-HBCD had changes 
in neural transcriptomic profiles (calcium 
signaling) and proteomic profiles (excito-
toxicity) (Rasinger et al. 2014), possibly 
inhibit ing sarcoplasmic-endoplasmic 
reticulum Ca2+ ATPase (Al-Mousa and 
Michelangeli 2014). Sixty-two children 
from randomly selected women who were 
part of the prospective Groningen infant 
COMPARE study noted to have detectable 
serum HBCD concentrations were found to 
have changes in coordination, verbal skills, 
and total intelligence (Roze et al. 2009). In 
a cross-sectional study of 515 Belgian adoles-
cents 14–17 years old, serum HBCD concen-
trations were not significantly correlated 
with neurobehavioral test scores or TH levels 
(Kiciński et al. 2012).
CM-HBCD stereoisomers are gamma 
(γ-HBCD; 75–89%), alpha (α-HBCD; 
10–13%), and beta (β-HBCD; 1–12%) 
(Heeb et al. 2005). γ-HBCD is highest in 
environmental matrices, while α-HBCD 
dominates humans and wildlife, demon-
strating the importance of stereoisomer-
specific biomonitoring and toxicity studies 
(Covaci et al. 2006). HBCD stereoisomer 
studies demonstrate differences in water solu-
bility, lipophilicity, structure, toxicokinetics, 
and metabolic pathways (Szabo et al. 2010, 
2011a). γ-HBCD is rapidly metabolized and 
eliminated (terminal half-life ~ 1–4 days) 
with limited bioaccumulation, and under-
goes in vivo stereoisomerization to β- and 
α-HBCD (Szabo et al. 2010). In contrast, 
α-HBCD’s terminal half-life is ~ 17 days, and 
it  bioaccumulates, with lipophilic-driven tissue 
distribution, and no in vivo stereoisomerization 
(Szabo et al. 2011a). The toxico kinetic differ-
ences account for stereoisomer shifts between 
γ-HBCD and α-HBCD. Szabo et al. (2011b) 
demonstrated that infantile mice exposed at 
PND10 (α-HBCD or γ-HBCD) had 10–25% 
increased body-burden over adults (PND60). 
Hakk et al. (2012) identified unique metabo-
lites via radiochemical detection in the urine 
and feces of α-HBCD and γ-HBCD-treated 
mice, further suggesting stereoisomers differ 
biologically and chemically. However, in vivo 
mammalian stereoisomer-specific toxicity 
studies are limited.
This study uses a non-targeted metabo-
lomics approach to predict potential DNT 
hazards from exposure to a commercial 
chemical mixture and individual stereoiso-
mers. Metabolomics enables the assessment 
of changes in levels of low-molecular weight 
endogenous compounds after chemical 
exposure. The goals of this study include 
a) develop a neonatal serum screening 
method to identify endogenous responses 
following CM-HBCD exposure; b) compare 
profiles between CM-HBCD, α-HBCD, and 
γ-HBCD; and c) determine metabolites asso-
ciated with treatment groups and that have 
been associated with DNT in other studies.
Methods and Materials
Chemicals
1,2,5,6,9,10-hexabromocyclododecane 
(CAS#3194-55-6) is CM-HBCD purchased 
from Sigma-Aldrich (St. Louis, MO). 
Stereoisomer separation and thermal conver-
sion were previously described (Szabo et al. 
2010, 2011a). Other chemicals utilized were 
purchased from Sigma-Aldrich (St. Louis, 
MO) at the highest purity level available.
Dosing Solutions
Doses were selected based on published DNT 
(Eriksson et al. 2006) and toxico kinetics 
(Szabo et al. 2010, 2011a, 2011b), and stereo-
isomer percentage in CM-HBCD, α-HBCD, 
γ-HBCD, and CM-HBCD were individually 
mixed with corn oil and toluene and evapo-
rated under vacuum; control solutions were 
generated using the same procedure. Mice were 
gavaged with 3, 10, or 30 mg/kg α-HBCD, 
3 and 30 mg/kg γ-HBCD, and 30 mg/kg 
CM-HBCD. The doses selected were designed 
to determine individual stereoisomer contri-
bution when compared to the commercial 
mixture [e.g., ~ 10% alpha (3 mg/kg) and 
90% gamma (30 mg/kg) metabolic profiles to 
the 30 mg/kg CM-HBCD].
Animals and Treatment
PND10 mice given a single oral exposure of 
0.9 mg/kg or 13.5 mg/kg HBCD displayed 
significant differences in spontaneous 
behavior at 3 months of age, and mice given 
the higher dose also had signs of impaired 
memory and learning (Eriksson et al. 2006) 
during a window of developmental neuro-
toxicity; therefore, this time point was 
selected for this metabolomic study. Mouse 
dams (n = 7) and female C57BL/6 pups 
(PND9, ~ 7 g) were purchased from Charles 
River Breeding Laboratories (Raleigh, NC), 
housed in an Association for Assessment and 
Accreditation of Laboratory Animal Care 
(AAALAC)-accredited facility, under the U.S. 
EPA’s National Health and Environmental 
Effects Research Laboratory (NHEERL) and 
Institutional Animal Care and Use Committee 
(IACUC) approval. Dams and six female pups 
per litter were acclimated (24 hr) in shoebox 
cages. PND10 female pups were gavaged with 
a single dose of vehicle control, α-HBCD, 
γ-HBCD, or CM-HBCD, at 10 mL/kg. 
Rodents were maintained on a 12-hr light/
dark cycle, ambient temperature (22°C), 
and relative humidity (56 ± 5%). Rodents 
were provided Purina 5001 Rodent Chow 
(Ralston Purina, St. Louis, MO) and tap water 
ad libitum. Three to six pups per treatment 
(one pup per litter) were sacrificed (decapi-
tation) 4 days following exposure, individu-
ally weighed, and blood harvested. Protocols 
involving animal use have been approved by 
an appropriate institutional committee, and 
animals have been treated humanely and with 
regard for alleviation of suffering.
Sample Preparation
We chose to measure blood metabolites 
on PND14 based on tissue concentra-
tions measured at same time point (Szabo 
et al. 2010, 2011a, 2011b), and allowance 
of ample time to capture metabolite forma-
tion. Serum was prepared and stored at –80°C 
until analyzed. Aliquot of 60 μL of serum was 
mixed with 80 μL of solution containing 5 mM 
formate, 0.2% NaN3 in D2O, and 260 μL of 
saline (0.9% NaCl in D2O); 400 μL of solution 
was transferred into 5 mm NMR tube.
Instrument and Data Acquisition
1H NMR spectra were acquired on Bruker 
Advance III 950 MHz instrument (located at 
DHMRI, Kannapolis, NC) using a CPMG 
pulse sequence (Beckonert et al. 2007) with 
water suppression (cpmgpr1d) during relax-
ation, a 2-sec relaxation delay, and 256 
scans. Spectra were acquired at 25°C, with 
32 k data points, and zero-filled and Fourier 
Transformed. Spectra were phase- and baseline-
corrected manually, and referenced to formate 
(8.44 ppm). The quality of NMR spectra was 
assessed for NMR line shape and width, signal 
to noise levels, alignment of identified markers. 
These are standard measures that ensure the 
quality of NMR data for further analysis. 
NMR peaks in the spectra had symmetric 
lorentzian line shapes with good signal to noise 
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ratio and appropriate line width ~ 1–1.5 Hz, 
demonstrated by the line width of the internal 
standard peak, formate. The chemical shift 
(position of the NMR peaks in the spectrum) 
is sensitive to factors such as pH and ionic 
strength in the sample. Characteristic peaks in 
serum samples such as glucose and lactate were 
used for alignment across the samples. All raw 
and processed data, metadata, and experimental 
procedures are available at the NIH common 
fund metabolomics workbench (http://www.
metabolomicsworkbench.com/).
Data Preprocessing
NMR data were preprocessed using traditional 
binning and quantitative approaches (Sumner 
et al. 2010; Pathmasiri et al. 2012). Binning 
was performed by automated integration 
with a 0.04 ppm bin width over the spectral 
window (excluding water suppression regions 
and formate signal), and bins were normal-
ized to total integral of each of the spectrum. 
Serum metabolites and concentrations were 
library matched with Chenomx NMR 
Suite 5.1 Professional software (Edmonton, 
Alberta) using the formate internal standard 
for relative integration. This software contains 
internal library adjustments for increments 
in chemical shift based on pH, and relax-
ation time of signal (Weljie et al. 2006). The 
following advantages of this method include: 
a) small increments in pH result in portions of 
metabolite signals aligning with different bins, 
while deconvolution circumvents issue, and 
b) multiple signals within separate bins.
NMR spectroscopy is  a quantita-
tive method and the area under the peak is 
directly proportional to the number of 
atoms (1H described in the current analysis) 
underlying the peak. The relative concentra-
tion of the metabolite(s) can be determined 
by using an internal standard with a known 
concentration and the integrals of the 
metabolite and internal standard peaks using 
the formula CM = CIS × (IM/IIS)(NIS/NM), 
where CM = concentration of metabolite, 
CIS = concentration of internal standard, 
IM = integral of metabolite peak, IIS = integral 
of the internal standard, NM = number 
of 1H atoms of the metabolite peak, and 
NIS = number of 1H atoms of the internal 
standard peak. The NMR solutions used in 
these samples contained 1 mM formate, hence, 
enabling the relative quantitation of metabo-
lites in the sample with respect to the formate 
internal standard. The Chenomx NMR library 
used for relative concentration determina-
tion contains a quantitative metabolite library 
where this formula is pre-built into software 
such that the concentration of metabolites can 
be directly obtained when the information 
about the internal standard and its concentra-
tion is given (Weljie et al. 2006). For subse-
quent data reduction from library matching, 
metabolite concentration was normalized 
to formate.
Data Reduction and Visualization
NMR data capture (metabolite ID and 
concentration or bin region and integral value) 
were transferred to SIMCA-P+ 12.0 software 
(Umetrics; Umeå, Sweden) for reduction and 
visualization. Normalized binned NMR data 
were Pareto scaled by dividing the integral of 
each bin by the reciprocal of the square root of 
the standard deviation for the bin and centered 
prior to multivariate analysis. Principal compo-
nent analysis (PCA) and partial least squares 
projection to latent structures discriminate 
analysis (PLS-DA) were conducted using 
SIMCA-P+ 12.0 for binned and concentra-
tion data. These pattern recognition methods 
are commonly used to analyze high dimen-
sional multicollinear data such as metabolo-
mics data (Trygg et al. 2007; Eriksson et al. 
2013). Loadings, variable influence on projec-
tions (VIP), and contribution plots were 
examined to determine bins or metabolites 
that best define group separation, which are 
commonly used multivariate statistical analysis 
approaches (Eriksson et al. 2013). The VIP 
statistic summarizes the importance of the bin 
in differentiating the phenotypic groups. The 
subset of bins or metabolites that had a VIP 
≥ 1.0 with a jack-knife confidence interval 
that did not include 0 were determined to be 
important for differentiating the study groups. 
All models used a 7-fold cross-validation to 
assess the predictive variation of the model 
(Q2) (Eriksson et al. 2013). In addition, 
Figure 1. 950 MHz 1H NMR spectrum of metabolites in a representative 60-μL mouse serum preparation. Signals for metabolites at higher concentration 
are labeled.
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metabolite concentrations were compared 
between treatment and dose groups to controls 
using Mann–Whitney U test.
Results
This study used 60 μL serum aliquots and 
enabled the library matching of 40 endo-
genous metabolites for the treatment and 
dose groups for samples collected on the 
fourth day following a single oral exposure 
at PND10 (see Table S1). No changes 
in body weight were observed between 
treated and control mice (data not shown). 
NMR signals assigned via Chenomx library 
matching identified essential and nonessen-
tial amino acids, alcohols, ketones, fatty-acid 
by-products, and sugars (Figure 1). Classes 
of compounds detected by the NMR method 
included amino acids (alanine, asparagine, 
arginine, cysteine, glycine, glutamate, gluta-
mine, homoserine, isoleucine, leucine, lysine, 
methionine, phenylalanine, sarcosine, serine, 
threonine, tyrosine, taurine, valine); alcohols 
(methanol and glycerol); ketones and fatty 
acid by-products (aceto acetate, acetate, 
3-hydroxybutyrate, acetone, pyruvate, isobu-
tyrate); sugar (glucose); other small molecule 
intermediates (o-phosphocholine, choline, 
n,n-dimethyl glycine, citrate, creatine, lactate, 
methylhistidine, succinate, myo-inositol, 
dimethylamine, methylsuccinate, and 
2-hydroxyisobutyrate).
Significant differences in the metabolite-
response levels and direction of change across 
treatment and dose groups are summarized 
in Table 1, and mean values of all metabo-
lites are listed according to treatment group 
in Table S1. Phenylalanine exhibited 
decreases, 36% and 42% (p = 0.02 and 0.03, 
respectively) from controls after exposure to 
γ-HBCD at 3 mg/kg and 30 mg/kg, respec-
tively. Glutamate exhibited dose-dependent 
decreases of 14%, 17%, and 28% (p = 0.37, 
0.05, and 0.05, respectively) in 3 mg/kg, 
10 mg/kg, and 30 mg/kg α-HBCD groups. 
Arginine was significantly decreased 30% 
and 48% (p = 0.05 and 0.02, respectively) in 
3 mg/kg from γ- and α-HBCD, respectively. 
O-phosphocholine and choline increased 29% 
(p = 0.05) and decreased 43% (p = 0.007) 
in 10 mg/kg and 30 mg/kg groups, respec-
tively, after α-HBCD exposure. Ketone 
bodies, acetoacetate and acetone, increased 
40% (p = 0.02) at 10 mg/kg and decreased 
28% (p = 0.03) at 30 mg/kg with α-HBCD 
exposure. Glycerol and taurine increased after 
CM-HBCD exposure by 18% (p = 0.02) and 
11% (p = 0.01), respectively. Compared with 
controls, serum metabolites display mean 
values either consistently elevated (> 0) across 
all treatment and dose groups (3-hydroxybu-
tyrate, creatine, valine, leucine) or lowered 
(< 0) across all treatment and dose groups 
(hemoserine, alanine, arginine), while all 
others display treatment- and dose-specific 
responses (see Table S1).
The PLS-DA of binned data for vehicle 
control (green), α-HBCD (blue), γ-HBCD 
(orange), and CM-HBCD (red) at 30-mg/kg 
group is displayed in Figure 2. The samples 
derived from mice exposed to either 
α-HBCD or γ-HBCD cluster and traject on 
one side of the vehicle control group, while 
samples from CM-HBCD cluster and traject 
on the other side of the vehicle control group. 
There is more variation between treatment 
and dose groups than within treatment 
groups. This qualitative metric is supported 
by observing the patterns of differentia-
tion for treatment and dose groups indicate 
increased similarity in metabolic profiles 
between mice exposed to same treatment and 
dose groups, compared with other groups.
PLS-DA analysis of the concentration data 
differentiates treatment- and dose-groups. 
Using α-HBCD profiles as an example, 
the 3 mg/kg, 10 mg/kg, and 30 mg/kg 
groups, and vehicle controls are presented in 
Table 1. Metabolites that were significantly higher or lower than controls in 60 μL serum aliquots from at 
least one group of HBCD-exposed mice.
Metabolite
α-HBCD γ-HBCD
Commercial 
HBCD
3 mg/kg  
n = 3
10 mg/kg  
n = 3
30 mg/kg  
n = 6
3 mg/kg  
n = 3
30 mg/kg  
n = 6
30 mg/kg  
n = 6
Increased 
Acetoacetate 1.05 ± 0.07 1.40 ± 0.14* 1.19 ± 0.35 1.05 ± 0.43 1.06 ± 0.05 –1.08 ± 0.02
Glycerol –1.11 ± 0.24 1.07 ± 0.41 –1.03 ± 0.09 1.2 ± 0.23 1.10 ± 0.23 1.18 ± 0.09*
O_phosphocholine –1.02 ± 0.10 1.29 ± 0.18* –1.01 ± 0.28 –1.01 ± 0.28 –1.09 ± 0.07 1.22 ± 0.14
Taurine 1.04 ± 0.40 1.08 ± 0.12 –1.00 ± 0.001 1.3 ± 0.83 1.07 ± 0.25 1.11 ± 0.64*
Pyruvate 1.10 ± 0.22 1.13 ± 0.36 1.39 ± 0.12* 1.08 ± 0.50 1.12 ± 0.27 1.00 ± 0.35
Decreased 
Acetone –1.02 ± 0.33 1.16 ± 0.5 –1.28 ± 0.5* 1.04 ± 0.01 1.00 ± 0.01 1.02 ± 0.33
Arginine –1.30 ± 0.018* –1.05 ± 0.20 –1.02 ± 0.36 –1.48 ± 0.95* –1.02 ± 0.29 –1.09 ± 0.44
Choline –1.06 ± 0.14 1.04 ± 0.13 –1.43 ± 0.01* 1.04 ± 0.17 –1.12 ± 0.29 1.14 ± 0.47
Glutamate –1.14 ± 0.21 –1.17 ± 0.06* –1.28 ± 0.06* 1.07 ± 0.18 –1.18 ± 0.14 1.05 ± 0.19
Phenylalanine 1.00 ± 0.30 –1.03 ± 0.04 –1.15 ± 0.13 –1.36 ± 0.55* –1.42 ± 0.16* –1.21 ± 0.04
Note: Values represent difference ± standard deviation. Mean values for all metabolites are presented in Table S1.
*Significantly different from control, p < 0.05. 
Figure 2. Multivariate analysis (PLS-DA score plot) of bin data obtained for serum from individual (n = 6/
treatment group) mice exposed to vehicle controls (green), or 30 mg/kg α-HBCD (blue), γ-HBCD (orange), 
or CM-HBCD (red) [R2X = 0.713; R2Y = 0.379; Q2 = 0.0307].
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a 2-dimensional PLS-DA scores plot 
(Figure 3A). PLS-DA was conducted using 
data for controls and 30 mg/kg (Figure 3B), 
and examination of loadings plots, variable 
importance plots, and contribution plots 
(not shown) enabled selection of a metabo-
lite subset (see “Methods and Materials”) 
that most contributed to group separation. 
Using only this metabolite subset, separa-
tion of α-HBCD from controls in PLS-DA 
(Figure 3C) improved, compared with the 
PLS-DA plot in Figure 3B, confirming that 
metabolite profiles are indeed distinct between 
groups. The process was repeated using 
γ-HBCD and CM-HBCD (control vs. each 
dose) to derive a list of distinct metabolites 
best distinguishing each group from other 
groups (Table 2). Although differentiation 
was achieved between all treatment and dose 
groups, PLS-DA analysis of the high-dose 
group concentration data (30 mg/kg) versus 
controls provided best separation (data 
not shown).
In both PLS-DA and NMR analyses, 
the CM-HBCD, α-HBCD, and γ-HBCD 
groups differentiated, representing exposure-
specific responses. The CM-HBCD metabo-
lomics pattern is more similar to γ-HBCD, 
than to α-HBCD (Figure 4). The differ-
ences between and among study groups was 
improved using concentration data, compared 
with using the binning results.
Discussion
This study aids the promise of metabolo-
mics in predicting developmental outcomes 
related to early-life exposures to mixtures 
and individual constituents of CM-HBCD. 
The impact of α-HBCD, γ-HBCD, and 
CM-HBCD on serum biochemical profiles 
4 days following acute exposure at PND10 
was investigated. Metabolite profiles for the 
HBCD treatment groups were distinct with 
a few metabolites in common. Based on prior 
knowledge, selected metabolites differenti-
ated the treatment and dose groups mapped 
to different biochemical pathways involving 
energy and amino acid metabolism that were 
identified, specifically, those metabolites 
involved with lipid metabolism and tricarbox-
ylic acid (TCA) cycle.
After CM-HBCD exposure, serum 
glycerol levels increased, an indication 
of accelerated lipolysis (lipid metabolism 
and breakdown) (Herrera and Amusquivar 
2000). Acetone, a ketone body, was signifi-
cantly lower in mice treated with 30 mg/kg 
α-HBCD compared with controls and may 
be a result of reduced conversion of aceto-
acetate to acetone further resulting in reduced 
conversion of acetone to pyruvate (statisti-
cally significant at same treatment and dose 
group), lactate, and acetate (non-statistically 
significant trend) (Table 1). Other indicators 
Figure 3. Score plot of PLS-DA analysis of metabolite concentration data for serum samples from mice 
administered (A) 0, 3, 10, and 30 mg/kg doses of α-HBCD, indicating separation between control (green) 
and dose groups [R2X = 0.664; R2Y = 0.693; Q2 = –0.11]; (B) vehicle control or 30 mg/kg α-HBCD showing 
clear separation of study groups (green, left, control; blue, right, α-HBCD) [R2X = 0.76; R2Y = 0.814; 
Q2 = 0.13]; (C) vehicle controls or 30 mg/kg α-HBCD showing improvement of separation of dose group 
from control group (green, left, control; blue, right, α-HBCD) [R2X = 0.504; R2Y = 0.915; Q2 = 0.538] was 
achieved using subset of metabolites that best defined groups (VIP ≥ 1.0 with 95% confidence interval that 
did not include 0). See Table 1 for numbers of mice per group.
(A)
(B)
(C)
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of accelerated lipolysis were seen with non-
statistical increased trends in two other ketone 
bodies, 3-hydroxybutyrate (all treatments; 
α-HBCD, γ-HBCD, or CM-HBCD) and 
acetoacetate (α-HBCD treatment only) (see 
Table S1), further supporting the possible 
connection between HBCD exposures and 
accelerated lipolysis. CM-HBCD effects 
on hepatic glucose and energy metabolism 
have been previously described in the litera-
ture (Cantón et al. 2008; van der Ven et al. 
2006). Rat hepatocytes treated 28 days with 
CM-HBCD altered gene expression that is 
involved in glucose metabolism (Cantón et al. 
2008). Liver glucose and lipid metabolism 
disturbances are classic hallmarks of obesity 
(Muoio and Newgard 2006) and chemical 
exposures during vulnerable windows of 
development may cause and contribute to this 
obesity (La Merrill and Birnbaum 2011). In 
a rat study, CM-HBCD exposure has been 
shown to suppresses serum TH levels (van der 
Ven et al. 2006). TH has been suspected to be 
involved in energy metabolism (Yanagisawa 
et al. 2014) leading to decreased energy 
metabolism and weight gain.
Elevated non-statistically significant 
trends in serum 3-hydroxybutyrate, creatine, 
and taurine response were a similar biomarker 
fingerprint profile in α-HBCD, γ-HBCD, 
and CM-HBCD (Figure 5). The specific 
biomarker profiles (3-hydroxybutyrate, 
creatine, and taurine), if observed and vali-
dated in subsequent longer duration and 
alternate species studies, could find use in 
prediction of HBCD exposure and DNT. 
3-Hydroxybutyrate, a ketone body used as 
energy by the brain when blood glucose is 
low, is essential during brain development, 
and increased levels are needed to nourish 
the brain during times of fasting or energy 
dysregulation (McKenna et al.  2015; 
Hawdon 1999). Creatine is important in the 
CNS, facilitating neurotransmitter release, 
membrane potential maintenance, Ca2+ 
homeostasis, and ion gradient restoration 
(Stockler et al. 2007). Creatine deficiency 
syndromes have common clinical mani-
festations, including cognitive dysfunction 
with mental retardation, poor language 
skills, and autism spectrum disorders 
(Mercimek-Mahmutoglu and Salomons 
2015; Tarnopolsky and Beal 2001). The 
observed increase in creatine and increase in 
o-phosphocholine may be related to effects 
on the SAM pathway (Brosnan et al. 2011). 
Taurine crosses the blood–brain barrier and 
is implicated in inhibitory neurotransmission, 
long-term potentiation (LTP) in striatum 
and hippocampus, membrane stabilization, 
adipose tissue regulation, possible obesity 
prevention, calcium homeostasis, protection 
against glutamate excitotoxicity, and epileptic 
seizure prevention in humans (Wu and 
Prentice 2010). The presence of 3-hydroxy-
butyrate, creatine, and taurine metabolites in 
all HBCD treatment groups may be driven by 
α-HBCD, considering γ-HBCD’s biological 
stereoisomerization to α-HBCD (Szabo et al. 
2010) and α-HBCD biological stability 
(Szabo et al. 2011a).
This metabolomics study also revealed 
stereoisomer-specific responses, with differ-
ences between isomers and their mixture. For 
α-HBCD, glutamate significantly decreased 
following mid- and high-dose exposures. The 
contribution of glutamate to synaptic trans-
mission, plasticity, and development is well 
established (Morello and Partanen 2015). 
For γ-HBCD, phenylalanine decreased 
significantly in both γ-HBCD dose groups. 
Phenylalanine is an essential amino acid highly 
concentrated in brain and blood, and the brain 
uses phenylalanine to produce norepineph-
rine, a neurotransmitter involved in synaptic 
transduction (Fernstrom and Fernstrom 
2007). Depletion of norepinephrine reduces 
LTP in dentate gyrus of rat hippocampus 
(Stanton and Sarvey 1985). Further research 
is merited to unravel the relationships between 
phenylalanine,  norepinephrine, effects on 
 hippocampus, and LTP.
To determine individual stereoisomer 
contribution to the commercial mixture 
Table 2. Metabolites important to the differentiation of treatment and control groups, using PLD-DA 
analysis (VIP ≥ 1.0 with a jack-knife confidence interval that did not include 0).
Exposure Increased relative to control Decreased relative to control
α-HBCD 3 mg/kg 3-hydroxybutyrate
Acetoacetate
Creatine
Leucine
Methionine
O-Phosphocholine
Taurine
Tyrosine
Valine
Alanine
Arginine
Glutamate
Lactate
Pyruvate
Serine
α-HBCD 10 mg/kg 3-hydroxybutyrate
Acetoacetate
Glutamine
Methionine
O-Phosphocholine
Taurine
Lactate
Methanol
N,N-Dimethylglycine
Phenylalanine
Pyruvate
Glutamate
α-HBCD 30 mg/kg 2-hydroxyisobutyrate
3-hydroxybutyrate
Acetoacetate
Glutamine
Leucine
Taurine
Valine
Acetate
Alanine
Choline
Citrate
Glutamate
Lactate
Methanol
Phenylalanine
Pyruvate
γ-HBCD 3 mg/kg 3-hydroxybutyrate
Citrate
Creatine
Glycerol
Glycine
Serine
Taurine 
Alanine
Asparagine
Cysteine
Lactate
Methanol
Phenylalanine
Pyruvate
γ-HBCD 30 mg/kg 2-hydroxyisobutyrate
3-hydroxybutyrate
Asparagine
Citrate
Creatine
Glucose
Glycerol
Glycine
Taurine
Choline
Glutamate
Lactate
Methanol
Phenylalanine
Pyruvate
Serine
Threonine
Tyrosine
CM-HBCD 30 mg/kg 3-hydroxybutyrate
Asparagine
Citrate
Creatine
Glycerol
Lactate
Methionine
O-Phosphocholine
Taurine
Valine
Alanine
Arginine
Glucose
Methanol
Phenylalanine
Note: VIP, variable influence on projections.
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effects observed in the literature, ~ 10% alpha 
(3 mg/kg) and 90% gamma (30 mg/kg) 
metabolic profiles were compared to the 
30 mg/kg CM-HBCD. Of the 15 metabo-
lites differentiating CM-HBCD from the two 
other treatment-groups, all 15 metabolites are 
seen to be contributed by either α-HBCD 
or γ-HBCD, with unique profiles between 
stereoisomers (Figure 5). This supports the 
hypothesis that α-HBCD and γ-HBCD indi-
vidually represent a fraction of CM-HBCD’s 
response, and both individual stereoisomers 
elicit specific and unique metabolite effects 
that differ from one another and with respect 
to CM-HBCD.
The α-HBCD metabolomics profile raises 
additional concerns, as α-HBCD is formed 
by stereoisomerization, bioaccumulates, and 
is the main stereoisomer in human serum and 
breast milk (Covaci et al. 2006). The metabo-
lites specific to α-HBCD differentiation by 
treatment and dose groups from the controls 
(not observed after exposure to CM-HBCD) 
included increases in the endogenous metabo-
lites acetoacetate, leucine, and tyrosine and 
decreases in glutamate, lactate, pyruvate, 
and serine (Figure 5). Current national risk 
assessments conducted by the EU, Canada, 
and Australia used CM-HBCD research 
investigations to derive regulatory risk values 
(Aylward and Hays 2011). Based on differ-
ences between stereoisomer toxico kinetics, 
molecular pathway identification, and serum 
metabolomics responses reported here, we 
recommend further HBCD stereoisomer-
specific studies and generation of α-HBCD-
specific human health risk assessment for 
public health protection.
Since metabolites represent end products 
of the genome and proteome, metabolomics 
holds promise of providing an integrated 
physiological phenotype (Merrick et al. 2011). 
Combining metabolomics with other omic 
techniques may contribute to an under-
standing of biological responses to xenobiotics. 
However, due to its relative infancy compared 
with conventional toxicity assays and other 
omics, metabolomics conducted on environ-
mental chemicals is sparse. With appropriate 
study design, metabolomics represents an 
opportunity to better understand the toxicity 
of environmental chemicals and their impact 
on human health.
In summary, we investigated the toxicity 
of CM-HBCD, α-HBCD, and γ-HBCD in 
neonatal mice using a metabolomics profiling 
approach. All treatment groups exhibited 
changes in metabolites involved in aerobic 
energy metabolism, lipolysis, neurodevelop-
ment, and amino acid metabolism. However, 
each treatment group clustered and separated 
from the others, signifying different biolog-
ical responses to each stereoisomer and the 
mixture. We demonstrate that metabolomics 
Figure 4. PLS-DA plot of metabolite concentrations derived from serum samples from mice administered 
vehicle control (green), or high dose (30 mg/kg) CM-HBCD (red), α-HBCD (blue), or γ-HBCD (orange) 
[R2X = 0.642; R2Y = 0.345; Q2 = –0.186] (n = 6 for all groups).
Figure 5. Endogenous serum metabolite increase and decrease after administration of CM-HBCD, 
α-HBCD, or γ-HBCD at 30 mg/kg, 3 mg/kg and 30 mg/kg, respectively, measured 4 days after an acute 
dose in infant mice. Contributions of each stereoisomer to the mixture at CM-HBCD relevant ratio 
~ 10%:90%::3 mg/kg:30 mg/kg::α-HBCD:γ-HBCD. Arrows indicate metabolites that were consistently 
increased (↑) or decreased (↓), or that had mixed responses (↑↓).
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is a promising approach to uncover differ-
ences between individual stereoisomers and 
their mixture, identify potential biomarkers 
of effects, and discover potential mechanistic 
links between HBCD exposures and disease 
and dysfunction.
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